Figure S1. IC_{50} values of curcumin were very weakly correlated with the levels of phosphorylated AKT in AML cell lines. (A) Western blot analysis of phosphorylated AKT protein (p-AKT) in AML cell lines. The numbers below the blots indicate the relative band intensity of p-AKT protein normalized against that of ACTB. (B) Pearson's correlation coefficient (r) between IC_{50} values of curcumin and the levels of phosphorylated AKT. IC_{50}, half maximal inhibitory concentration; AML, acute myeloid leukemia.



Table SI. Differentially phosphorylated proteins in ML-2 cells between treatment with curcumin (CCM) and DMSO (NC).

ProteinID	AveExp.CCM	AveExp.NC	logFC	Foldchange	CCM.1	CCM.2	NC.1	NC.2
MSK2	10.29039939	10.84945172	-0.55905	0.67874787	1278.08	1225.14	2322.13	1464.37
Raf-1	10.73813153	11.26534785	-0.52722	0.693892308	1499.13	1943.78	2108	2872.02
PRAS40	11.26678496	11.68686457	-0.42008	0.747383378	2839.22	2136.61	3279	3312.75
AKT	11.26802132	11.67499872	-0.40698	0.754201853	2519.89	2411.52	3225	3313.25
Stat5 (Tyr694)	10.00931277	10.36844371	-0.35913	0.77963408	1125.06	942.29	1154.5	1511.36
c-Fos	8.203546683	8.536863944	-0.33332	0.793709368	308.28	279.98	364	376.93
P70S6k	10.03558023	10.36355835	-0.32798	0.796652183	1122.88	979.17	1355.5	1278.57
JAK1 (Tyr1022)	11.90282935	12.21087291	-0.30804	0.807736388	4180.24	3505.81	5350	4198.94
c-Jun	8.848675135	9.147638201	-0.29896	0.812836411	461.77	458.27	559.5	572.92
P27	10.93566596	11.23408829	-0.29842	0.813141126	2093.84	1830.37	2518.5	2301.93
RSK2	10.32352971	10.62016268	-0.29663	0.814150282	1369.87	1196.81	1526.13	1621.18
NFκB (S536)	12.17311278	12.46752739	-0.29441	0.815403123	4137.53	5152.45	7324	4378.17
RPS6	11.52780009	11.81689986	-0.2891	0.818412583	3081.12	2827.64	3738.5	3479.72
4E-BP1	12.57799288	12.86032476	-0.28233	0.822260893	4691.99	7965.3	9663.5	5720.47
SHP1 (Ser591)	12.03594686	11.76612594	0.269821	1.205658163	6194.92	2845.14	3527.5	3437.14
RSK1	11.49507145	11.16078629	0.334285	1.260752564	2632.73	3162.38	2355.13	2223.66
Smad1	7.833416568	7.326554647	0.506862	1.420956038	189.25	272.44	185	137.52
Stat2 (Tyr689)	11.87996291	11.37124965	0.508713	1.422780646	3541.76	4008.67	2715.5	2582.24

Table SII. The 20 most enriched KEGG pathways.

KEGG pathway	p.adjust	Proteins	Count	Enrich factor
PD-L1/PD-1 pathway in cancer	5.30E-10	RAF1/AKT1/FOS/RPS6KB1/JAK1/JUN/RELA/PTPN6	8	42.38466623
Acute myeloid leukemia	8.81E-08	RAF1/AKT1/STAT5A/RPS6KB1/RELA/EIF4EBP1	6	42.22651449
ErbB signaling pathway	9.84E-09	RAF1/AKT1/STAT5A/RPS6KB1/JUN/CDKN1B/EIF4EBP1	7	38.83183391
EGFR-TKI resistance	2.02E-07	RAF1/AKT1/RPS6KB1/JAK1/RPS6/EIF4EBP1	6	35.81236039
B cell receptor signaling pathway	2.17E-07	RAF1/AKT1/FOS/JUN/RELA/PTPN6	6	34.50215208
Prolactin signaling pathway	2.08E-06	RAF1/AKT1/STAT5A/FOS/RELA	5	33.68067227
Pancreatic cancer	2.82E-06	RAF1/AKT1/RPS6KB1/JAK1/RELA	5	31.02167183
Chronic myeloid leukemia	2.82E-06	RAF1/AKT1/STAT5A/CDKN1B/RELA	5	31.02167183
Leishmaniasis	2.86E-06	FOS/JAK1/JUN/RELA/PTPN6	5	30.61879297
Endocrine resistance	4.48E-07	RAF1/AKT1/FOS/RPS6KB1/JUN/CDKN1B	6	28.86914766
Choline metabolism in cancer	4.48E-07	RAF1/AKT1/FOS/RPS6KB1/JUN/EIF4EBP1	6	28.86914766
Measles	9.47E-09	AKT1/STAT5A/FOS/JAK1/JUN/CDKN1B/RELA/STAT2	8	27.33503836
T cell receptor signaling pathway	5.83E-07	RAF1/AKT1/FOS/JUN/RELA/PTPN6	6	27.20361991
HIF-1 signaling pathway	6.54E-07	AKT1/RPS6KB1/CDKN1B/RELA/RPS6/EIF4EBP1	6	25.95574744
Hepatitis B	1.72E-08	RAF1/AKT1/STAT5A/FOS/JAK1/JUN/RELA/STAT2	8	23.28540305
Osteoclast differentiation	1.48E-06	AKT1/FOS/JAK1/JUN/RELA/STAT2	6	22.10294118
mTOR signaling pathway	2.35E-07	RAF1/AKT1S1/AKT1/RPS6KB1/RPS6/EIF4EBP1/RPS6KA1	7	21.57324106
KSHV infection	6.08E-07	RAF1/AKT1/FOS/JAK1/JUN/RELA/STAT2	7	17.74573055
Human papillomavirus infection	1.34E-06	RAF1/AKT1/RPS6KB1/JAK1/CDKN1B/RELA/EIF4EBP1/STAT2	8	11.43101604
PI3K-Akt signaling pathway	2.02E-06	RAF1/AKT1/RPS6KB1/JAK1/CDKN1B/RELA/RPS6/EIF4EBP1	8	10.6560319